Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
Condition(s) studied
Investigational drug(s) / intervention(s)
Observational study: This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Study summary
This observational, retrospective study aims to understand the treatment patterns and outcomes of patients with pulmonary and extra-pulmonary neuroendocrine carcinomas (NEC) in Latin America (Brazil, Mexico, Argentina, and Peru). The research will collect data from medical records to analyze factors like patient demographics, diagnosis methods, tumor characteristics, treatment approaches, and disease progression. The study is non-interventional, meaning patient care will follow standard clinical practice, with data gathered via an electronic system.
Eligibility
Primary outcome measure(s)
- Patterns of Initial Cancer Treatment: number of participants treated within vs. outside high-volume sites and associated treatment characteristics — Throughout the study period, an average of 24 months
Treatment patterns will be analyzed descriptively using tables and graphs to illustrate the distribution of patients receiving initial cancer treatment within versus outside high-volume treatment centers. Key characteristics of the initial treatment will be assessed. - Event-free survival (EFS) — Throughout the study period, an average of 24 months
defined as time from diagnosis until relapse, death, or definitive failure of treatment strategy that implicates failure of curative-intent treatment \[for patients treated with curative intent\]. Participants who are lost to follow up or reach the study end will be censored at their last date of contact. - Time to treatment failure (TTF) — Throughout the study period, an average of 24 months
in first and second-line: defined as time from first dose of treatments until date of discontinuation of treatment for any reason, including progression of disease, treatment toxicity, and death. Participants who are lost to follow up or reach the study end will be censored at their last date of contact - Progression-free survival (PFS) — Throughout the study period, an average of 24 months
defined as time from treatment initiation until progression or death \[for patients treated with palliative intent\]. Participants who are lost to follow up or reach the study end will be censored at their last date of contact. - Overall survival — Throughout the study period, an average of 24 months
\[according to disease stage/setting\], defined as time from initial diagnosis until date of death from any cause. Participants who are lost to follow up or reach the study end will be censored at their last date of contact. - Frequency of DLL-3 immunohistochemistry expression — After the end of recruitment, an average of 1 year
Rate of patients with DLL3 expression in extra-pulmonary and pulmonary NEC by IHC \[stratified by tumor primary site\]
Trial sites (19)
| Facility | City | Region | Status |
|---|---|---|---|
| Hospital Británico de Buenos Aires | Buenos Aires | Buenos Aires | Recruiting |
| Hospital de Gastroenterología Carlos Bonorino Udaondo | Buenos Aires | Buenos Aires | Recruiting |
| Instituto Alexander Fleming | Buenos Aires | Buenos Aires | Recruiting |
| Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO) | Cachoeiro de Itapemirim | Espírito Santo | Active Not Recruiting |
| Clínica Prognóstica - Centro de Pesquisa Clínica Onconeo | Campo Grande | Mato Grosso do Sul | Active Not Recruiting |
| Oncocentro de Minas Gerais (Oncoclínicas) | Belo Horizonte | Minas Gerais | Active Not Recruiting |
| IOP Pesquisa - Instituto de Oncologia do Paraná | Curitiba | Paraná | Active Not Recruiting |
| HCL - Hospital do Câncer de Londrina | Londrina | Paraná | Active Not Recruiting |
| INCA - Instituto Nacional de Câncer | Rio de Janeiro | Rio de Janeiro | Active Not Recruiting |
| HUOL - Hospital Universitário Onofre Lopes da UFRN | Natal | Rio Grande do Norte | Active Not Recruiting |
| Liga Norte Riograndense Contra o Câncer | Natal | Rio Grande do Norte | Active Not Recruiting |
| HMV - Hospital Moinhos de Vento | Porto Alegre | Rio Grande do Sul | Active Not Recruiting |
| Futtura Oncologia - Hub de Pesquisa Clínica | Porto Alegre | Rio Grande do Sul | Active Not Recruiting |
| ANIMI - Unidade de Tratamento Oncológico | Lages | Santa Catarina | Active Not Recruiting |
| A.C. Camargo Cancer Center | São Paulo | São Paulo | Active Not Recruiting |
| HIAE - Hospital Israelita Albert Einstein | São Paulo | São Paulo | Active Not Recruiting |
| Centro Oncológico Internacional (COI) | Mexico City | Mexico City | Active Not Recruiting |
| INCan - Instituto Nacional de Cancerología | Mexico City | Mexico City | Active Not Recruiting |
| Oncosalud AUNA | Lima | Lima Province | Recruiting |
More Latin American Cooperative Oncology Group trials in Brazil
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07192991 on ClinicalTrials.gov ↗ ← All trials in Brazil